Connection

Bonaventura Clotet to HIV Infections

This is a "connection" page, showing publications Bonaventura Clotet has written about HIV Infections.
Connection Strength

1.348
  1. Efficacy of single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide in the treatment of HIV-1. Expert Opin Pharmacother. 2018 Jun; 19(8):929-934.
    View in: PubMed
    Score: 0.118
  2. Pharmacokinetics of darunavir/cobicistat and etravirine alone and co-administered in HIV-infected patients. J Antimicrob Chemother. 2018 03 01; 73(3):732-737.
    View in: PubMed
    Score: 0.116
  3. Aging in HIV-Infected Subjects: A New Scenario and a New View. Biomed Res Int. 2017; 2017:5897298.
    View in: PubMed
    Score: 0.114
  4. Pneumocystis jirovecii pneumonia in HIV-1-infected patients in the late-HAART era in developed countries. Scand J Infect Dis. 2013 Aug; 45(8):635-44.
    View in: PubMed
    Score: 0.082
  5. Variability in non-nucleoside reverse transcriptase and protease inhibitors concentrations among HIV-infected adults in routine clinical practice. Br J Clin Pharmacol. 2007 Jun; 63(6):715-21.
    View in: PubMed
    Score: 0.054
  6. Lopinavir/ritonavir plus nevirapine as a nucleoside-sparing approach in antiretroviral-experienced patients (NEKA study). J Acquir Immune Defic Syndr. 2005 Jan 01; 38(1):47-52.
    View in: PubMed
    Score: 0.047
  7. Routine Screening of Anal Cytology in Persons With Human Immunodeficiency Virus and the Impact on Invasive Anal Cancer: A Prospective Cohort Study. Clin Infect Dis. 2020 07 11; 71(2):390-399.
    View in: PubMed
    Score: 0.034
  8. NEU Screen Shows High Accuracy in Detecting Cognitive Impairment in Older Persons Living With HIV. J Assoc Nurses AIDS Care. 2019 Jan-Feb; 30(1):35-41.
    View in: PubMed
    Score: 0.031
  9. Aging and the evolution of comorbidities among HIV-positive individuals in a European cohort. AIDS. 2018 10 23; 32(16):2405-2416.
    View in: PubMed
    Score: 0.030
  10. Antibodies and Antibody Derivatives: New Partners in HIV Eradication Strategies. Front Immunol. 2018; 9:2429.
    View in: PubMed
    Score: 0.030
  11. Mechanisms That Contribute to a Profound Reduction of the HIV-1 Reservoir After Allogeneic Stem Cell Transplant. Ann Intern Med. 2018 11 20; 169(10):674-683.
    View in: PubMed
    Score: 0.030
  12. Clinically relevant thresholds for ultrasensitive HIV drug resistance testing: a multi-country nested case-control study. Lancet HIV. 2018 11; 5(11):e638-e646.
    View in: PubMed
    Score: 0.030
  13. High risk and probability of progression to osteoporosis at 10 years in HIV-infected individuals: the role of PIs. J Antimicrob Chemother. 2018 09 01; 73(9):2452-2459.
    View in: PubMed
    Score: 0.030
  14. Incidence of cervical high-grade squamous intraepithelial lesions in HIV-1-infected women with no history of cervical pathology: up to 17 years of follow-up. Int J STD AIDS. 2019 01; 30(1):56-63.
    View in: PubMed
    Score: 0.030
  15. Low nadir CD4+ T-cell counts predict gut dysbiosis in HIV-1 infection. Mucosal Immunol. 2019 01; 12(1):232-246.
    View in: PubMed
    Score: 0.030
  16. Effectiveness of physically ablative and pharmacological treatments for anal condyloma in HIV-infected men. PLoS One. 2018; 13(8):e0199033.
    View in: PubMed
    Score: 0.030
  17. CD32 expression is associated to T-cell activation and is not a marker of the HIV-1 reservoir. Nat Commun. 2018 07 16; 9(1):2739.
    View in: PubMed
    Score: 0.030
  18. High Prevalence of Sarcopenia in HIV-Infected Individuals. Biomed Res Int. 2018; 2018:5074923.
    View in: PubMed
    Score: 0.030
  19. Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial. J Antimicrob Chemother. 2018 07 01; 73(7):1965-1971.
    View in: PubMed
    Score: 0.030
  20. Impact of intensification with raltegravir on HIV-1-infected individuals receiving monotherapy with boosted PIs. J Antimicrob Chemother. 2018 07 01; 73(7):1940-1948.
    View in: PubMed
    Score: 0.030
  21. Control of HIV-1 Pathogenesis in Viremic Nonprogressors Is Independent of Gag-Specific Cytotoxic T Lymphocyte Responses. J Virol. 2018 06 15; 92(12).
    View in: PubMed
    Score: 0.029
  22. Recurrent coronary disease in HIV-infected patients: role of drug-drug interactions. Br J Clin Pharmacol. 2018 07; 84(7):1617-1619.
    View in: PubMed
    Score: 0.029
  23. Memory B cell dysregulation in HIV-1-infected individuals. AIDS. 2018 Jan 14; 32(2):149-160.
    View in: PubMed
    Score: 0.029
  24. Evaluation of the Innate Immune Modulator Acitretin as a Strategy To Clear the HIV Reservoir. Antimicrob Agents Chemother. 2017 11; 61(11).
    View in: PubMed
    Score: 0.028
  25. Elevated humoral response to cytomegalovirus in HIV-infected individuals with poor CD4+ T-cell immune recovery. PLoS One. 2017; 12(9):e0184433.
    View in: PubMed
    Score: 0.028
  26. Preserved immune functionality and high CMV-specific T-cell responses in HIV-infected individuals with poor CD4+ T-cell immune recovery. Sci Rep. 2017 09 15; 7(1):11711.
    View in: PubMed
    Score: 0.028
  27. Transdermal rivastigmine for HIV-associated cognitive impairment: A randomized pilot study. PLoS One. 2017; 12(8):e0182547.
    View in: PubMed
    Score: 0.028
  28. Optimal Use of Transient Elastography and Acoustic Radiation Force Impulse to Stage Liver Fibrosis in HIV/HCV-Coinfected Patients in Clinical Practice. J Ultrasound Med. 2018 Jan; 37(1):113-121.
    View in: PubMed
    Score: 0.028
  29. Reduced darunavir dose is as effective in maintaining HIV suppression as the standard dose in virologically suppressed HIV-infected patients: a randomized clinical trial. J Antimicrob Chemother. 2015 Apr; 70(4):1139-45.
    View in: PubMed
    Score: 0.023
  30. Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe. BMC Infect Dis. 2014 Jul 21; 14:407.
    View in: PubMed
    Score: 0.023
  31. Stable HIV-1 integrase diversity during initial HIV-1 RNA decay suggests complete blockade of plasma HIV-1 replication by effective raltegravir-containing salvage therapy. Virol J. 2013 Dec 05; 10:350.
    View in: PubMed
    Score: 0.022
  32. Changes in T-cell subsets in HIV-HCV-coinfected patients during pegylated interferon-alpha2a plus ribavirin treatment. Antivir Ther. 2010; 15(3):333-42.
    View in: PubMed
    Score: 0.016
  33. On the steps of cell-to-cell HIV transmission between CD4 T cells. Retrovirology. 2009 Oct 13; 6:89.
    View in: PubMed
    Score: 0.016
  34. Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks. J Acquir Immune Defic Syndr. 2005 Dec 01; 40(4):413-21.
    View in: PubMed
    Score: 0.012
  35. Role of viral kinetics under HCV therapy in HIV/HCV-coinfected patients. J Antimicrob Chemother. 2005 Jun; 55(6):824-7.
    View in: PubMed
    Score: 0.012
  36. [Spanish GESIDA/Nacional AIDS Plan Recommendations for antiretroviral therapy in HIV-infected Adults (October 2004)]. Enferm Infecc Microbiol Clin. 2004 Dec; 22(10):564-642.
    View in: PubMed
    Score: 0.012
  37. RNA editing by ADAR1 regulates innate and antiviral immune functions in primary macrophages. Sci Rep. 2017 10 17; 7(1):13339.
    View in: PubMed
    Score: 0.007
  38. Gag-protease coevolution analyses define novel structural surfaces in the HIV-1 matrix and capsid involved in resistance to Protease Inhibitors. Sci Rep. 2017 06 16; 7(1):3717.
    View in: PubMed
    Score: 0.007
  39. SAMHD1 is active in cycling cells permissive to HIV-1 infection. Antiviral Res. 2017 06; 142:123-135.
    View in: PubMed
    Score: 0.007
  40. [Costs and cost effectiveness analysis of preferred GESIDA regimens for initial antiretroviral therapy]. Enferm Infecc Microbiol Clin. 2011 Dec; 29(10):721-30.
    View in: PubMed
    Score: 0.005
  41. Genotypic and phenotypic evolution of HIV type-1 protease during in vitro sequential or concomitant combination of atazanavir and amprenavir. Antivir Ther. 2010; 15(3):431-6.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.